|
|
Volumn 15, Issue 2, 2008, Pages 99-106
|
|
The clinical significance of exhaled nitric oxide in asthma
a
b,c
|
|
Author keywords
Airways inflammation; Asthma; Exhaled nitric oxide
|
|
Indexed keywords
BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;
BRONCHODILATING AGENT;
BUDESONIDE;
CORTICOSTEROID;
FLUTICASONE;
FLUTICASONE PROPIONATE PLUS SALMETEROL;
LEUKOTRIENE RECEPTOR BLOCKING AGENT;
METHACHOLINE;
MONTELUKAST;
NITRIC OXIDE;
PLACEBO;
PRANLUKAST;
SALMETEROL;
THEOPHYLLINE;
ASTHMA;
BRONCHOSPASM;
BRONCHUS BIOPSY;
BRONCHUS HYPERREACTIVITY;
CLINICAL TRIAL;
CORRELATION ANALYSIS;
DIAGNOSTIC VALUE;
DISEASE CONTROL;
DISEASE EXACERBATION;
DISEASE SEVERITY;
DRUG DOSE COMPARISON;
DRUG DOSE REDUCTION;
DRUG MEGADOSE;
DRUG USE;
EMBASE;
EOSINOPHIL COUNT;
EXHALATION;
FIBEROPTIC BRONCHOSCOPY;
FORCED EXPIRATORY VOLUME;
HUMAN;
LUNG LAVAGE;
MEDICAL ASSESSMENT;
MEDICAL DECISION MAKING;
MEDICAL LITERATURE;
MEDLINE;
NON INVASIVE MEASUREMENT;
PATIENT CARE;
PATIENT MONITORING;
PEAK EXPIRATORY FLOW;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
PROVOCATION TEST;
RELIABILITY;
RESPIRATORY TRACT INFLAMMATION;
REVIEW;
SPUTUM ANALYSIS;
SYMPTOM;
TREATMENT OUTCOME;
|
|
EID: 43549117282
PISSN: 11982241
EISSN: None
Source Type: Journal
DOI: 10.1155/2008/463762 Document Type: Review |
|
Times cited : (25)
|
|
References (50)
|
